Amyloidosis: Graviores morbos, asperis remedii

Jayesh Mehta*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

3 Scopus citations


In this issue of Blood, Sanchorawala and colleagues provide 10-year follow-up of their efforts to treat immunoglobulin light chain (AL) amyloidosis with high-dose melphalan in the 1990s. They report median survival durations approaching 5 years for all patients and exceeding 10 years for those attaining hematologic complete remission.

Original languageEnglish (US)
Pages (from-to)3490-3491
Number of pages2
Issue number10
StatePublished - Nov 15 2007

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Amyloidosis: Graviores morbos, asperis remedii'. Together they form a unique fingerprint.

Cite this